JP2007504174A5 - - Google Patents

Download PDF

Info

Publication number
JP2007504174A5
JP2007504174A5 JP2006525016A JP2006525016A JP2007504174A5 JP 2007504174 A5 JP2007504174 A5 JP 2007504174A5 JP 2006525016 A JP2006525016 A JP 2006525016A JP 2006525016 A JP2006525016 A JP 2006525016A JP 2007504174 A5 JP2007504174 A5 JP 2007504174A5
Authority
JP
Japan
Prior art keywords
disorders
epilepsy
pharmaceutical composition
pain
depression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006525016A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007504174A (ja
Filing date
Publication date
Priority claimed from US10/655,393 external-priority patent/US7186726B2/en
Application filed filed Critical
Publication of JP2007504174A publication Critical patent/JP2007504174A/ja
Publication of JP2007504174A5 publication Critical patent/JP2007504174A5/ja
Pending legal-status Critical Current

Links

JP2006525016A 2003-09-03 2004-09-03 カルシウムチャネル遮断薬として使用されるピペラジン置換化合物 Pending JP2007504174A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/655,393 US7186726B2 (en) 1998-06-30 2003-09-03 Preferentially substituted calcium channel blockers
PCT/CA2004/001629 WO2005021523A1 (en) 2003-09-03 2004-09-03 Piperazine substituted compounds used as calcium channel blockers

Publications (2)

Publication Number Publication Date
JP2007504174A JP2007504174A (ja) 2007-03-01
JP2007504174A5 true JP2007504174A5 (enExample) 2007-10-18

Family

ID=34273458

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006525016A Pending JP2007504174A (ja) 2003-09-03 2004-09-03 カルシウムチャネル遮断薬として使用されるピペラジン置換化合物

Country Status (12)

Country Link
US (2) US7186726B2 (enExample)
EP (1) EP1670775A4 (enExample)
JP (1) JP2007504174A (enExample)
CN (1) CN1871225A (enExample)
AU (1) AU2004268711A1 (enExample)
BR (1) BRPI0414094A (enExample)
CA (1) CA2537487A1 (enExample)
IL (1) IL174025A0 (enExample)
MX (1) MXPA06002467A (enExample)
NZ (1) NZ546254A (enExample)
WO (1) WO2005021523A1 (enExample)
ZA (1) ZA200602684B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040266784A1 (en) * 1998-06-30 2004-12-30 Snutch Terrance P. Calcium channel inhibitors comprising benzhydril spaced from piperazine
US20060084660A1 (en) * 1998-06-30 2006-04-20 Neuromed Technologies Inc. Calcium channel blockers comprising two benzhydril moieties
US20040259866A1 (en) * 1998-06-30 2004-12-23 Snutch Terrance P. Calcium channel blockers comprising two benzhydril moieties
US7186726B2 (en) * 1998-06-30 2007-03-06 Neuromed Pharmaceuticals Ltd. Preferentially substituted calcium channel blockers
US6951862B2 (en) * 1998-06-30 2005-10-04 Neuromed Technologies, Inc. Calcium channel blockers comprising two benzhydril moieties
US7151102B2 (en) * 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
EP1745042A4 (en) * 2004-04-09 2010-07-14 Neuromed Pharmaceuticals Ltd DIARYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
KR20070063526A (ko) * 2004-08-30 2007-06-19 뉴로메드 파머큐티칼즈 리미티드 칼슘 채널 차단제인 우레아 유도체
US7511077B2 (en) * 2005-02-09 2009-03-31 Neuromed Pharmaceuticals Ltd. Diamine calcium channel blockers
EP1871372A4 (en) * 2005-04-08 2010-06-02 Neuromed Pharmaceuticals Ltd COMBINATION THERAPY WHICH INCLUDES AN AGENT BLOCKING CALCIUM CHANNELS OF TYPE N FOR THE RELIEF OF PAIN
WO2006124865A2 (en) * 2005-05-19 2006-11-23 Vertex Pharmaceuticals Incorporated Biaryls derivatives useful as modulators of ion channels
WO2006130493A2 (en) 2005-05-31 2006-12-07 Vertex Pharmaceuticals Incorporated Heterocycles useful as modulators of ion channels
EP1976841A4 (en) * 2005-12-19 2010-07-28 Neuromed Pharmaceuticals Ltd HETEROCYCLIC AMIDDERIVES AS CALCIUM CHANNEL BLOCKERS
CA2643924A1 (en) * 2006-04-17 2007-10-25 Neuromed Pharmaceuticals Ltd. Isoxazole derivatives as calcium channel blockers
US8362021B2 (en) * 2006-05-11 2013-01-29 Zalicus Pharmaceuticals Ltd. Method for increasing the bioavailability of benzhydryl piperazine containing compounds
US20100029681A1 (en) * 2006-05-26 2010-02-04 Hassan Pajouhesh Heterocyclic compounds as calcium channel blockers
EP2061780A4 (en) * 2006-09-14 2010-12-22 Zalicus Pharmaceuticals Ltd DIARYLE PIPERIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS
EP2074105A4 (en) * 2006-10-13 2010-10-06 Neuromed Pharmaceuticals Ltd CYCLOPROPYL-PIPERAZINE COMPOUNDS AS CALCIUM INHIBITORS
UY30639A1 (es) * 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
WO2008050200A1 (en) * 2006-10-24 2008-05-02 Pfizer Products Inc. Oxadiazole compounds as calcium channel antagonists
US20080139578A1 (en) * 2006-11-30 2008-06-12 Catherine Abbadie Substituted piperizines for the treatment of pain
GB0700893D0 (en) 2007-01-17 2007-02-21 King S College London Male contraceptive
PL2149560T3 (pl) 2007-05-22 2015-10-30 Astellas Pharma Inc 1-podstawiony związek tetrahydroizochinolinowy
AU2008313467B2 (en) * 2007-10-17 2013-08-29 Kudos Pharmaceuticals Limited 4- [3- (4-cyclopropanecarbonyl-piperazine-1-carbonyl) -4 -fluoro-benzyl] -2H-phthalazin-1-one
WO2009132454A1 (en) * 2008-04-28 2009-11-05 Neuromed Pharmaceuticals Ltd. Di-t-butylphenyl piperazines as calcium channel blockers
WO2009132452A1 (en) * 2008-04-28 2009-11-05 Neuromed Pharmaceuticals Ltd. Diaryl-cyclylalkyl derivatives as calcium channel blockers
BR122021018683B1 (pt) * 2008-10-07 2022-11-16 Kudos Pharmaceuticals Limited Formulação farmacêutica de 4-[3-(4-ciclopropanocarbonil- piperazina-1-carbonil)-4-flúor- benzil]-2h-ftalazin-1-ona, uso de um polímero de matriz, forma de dosagem e método para produzir uma dispersão amorfa sólida
ES2703176T3 (es) 2010-03-11 2019-03-07 Univ New York Compuestos amido como moduladores de RORgammat y usos de los mismos
US8409560B2 (en) 2011-03-08 2013-04-02 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
EP2654726A1 (en) 2011-03-08 2013-10-30 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
HK1199839A1 (en) 2011-09-09 2015-07-24 New York University Amido compounds as ror-gamma-tmodulators and uses thereof
CN103130745B (zh) * 2011-11-28 2017-03-15 中国人民解放军军事医学科学院毒物药物研究所 二芳基哌嗪类化合物及其医药用途
CN105218501A (zh) * 2014-07-03 2016-01-06 南京大学 含哌嗪环的香豆素类衍生物及其制备与在抗菌药物中的应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB920416A (en) 1958-04-04 1963-03-06 Lakeside Lab Inc Piperazino compounds
GB1051527A (enExample) * 1964-07-31
BG17385A1 (enExample) 1971-11-09 1973-11-10
US3997539A (en) 1974-05-31 1976-12-14 American Hoechst Corporation 3-(4-Acylaminopiperazin-1-yl alkyl)indoles, precursors and processes for the preparation thereof
US4188485A (en) * 1978-06-16 1980-02-12 G. D. Searle & Co. 1-[(10,11-Dihydro-5H-dibenzo[a,d]-cyclohepten-5-yl)methyl]-4-substituted piperidines and related compounds
ES8304135A3 (es) 1981-07-06 1983-01-01 Ferrer Int Procedimiento de obtencion de benzhidrilpiperazinas
ES514167A0 (es) 1982-07-20 1983-04-01 Ferrer Int "procedimiento de obtencion de benzhidrilpiperazinas".
JPS61155358A (ja) 1984-12-21 1986-07-15 Suntory Ltd ジアリール酪酸誘導体
FR2584723B1 (fr) 1985-07-09 1988-02-12 Adir Nouveaux derives du dihydro-2,3 benzofuranne, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
DE3600390A1 (de) * 1986-01-09 1987-07-16 Hoechst Ag Diarylalkyl-substituierte alkylamine, verfahren zu ihrer herstellung, ihre verwendung sowie sie enthaltende arzneimittel
US5386025A (en) * 1990-02-20 1995-01-31 The Salk Institute Biotechnology/Industrial Associates Calcium channel compositions and methods
IE73232B1 (en) 1990-05-25 1997-05-21 Akzo Nv Isochromane derivatives
US5703071A (en) * 1990-08-29 1997-12-30 Pharmacia & Upjohn Company Tropolone derivatives and pharmaceutical composition thereof for preventing and treating ischemic diseases
TW205034B (enExample) * 1990-09-13 1993-05-01 Pola Kasei Kogyo Kk
ES2024991A6 (es) * 1990-12-27 1992-03-01 Uriach & Cia Sa J Procedimiento para la obtencion de piperazinilcarboxamidas.
ES2027897A6 (es) 1991-01-24 1992-06-16 Espanola Prod Quimicos Procedimiento de preparacion de nuevos derivados de la difenilmetilpiperacina.
DE4111861A1 (de) * 1991-04-11 1992-10-15 Schwabe Willmar Gmbh & Co Benzopyranone, verfahren zu ihrer herstellung und verwendung
KR950704284A (ko) 1992-12-22 1995-11-17 데이비드 로버츠 칼슘 채널 길항제로서의 피페리딘 유도체(Piperidine Derivatives as Calcium Channel Antagonists)
JP3204424B2 (ja) * 1993-02-18 2001-09-04 三菱化学フォームプラスティック株式会社 ポリプロピレン系樹脂発泡粒子
PT682664E (pt) * 1993-12-08 2001-06-29 Alcon Laboratoires Inc Compostos possuindo actividade potente como antagonistas do calcio e anti-oxidantes e sua utilizacao como agentes citoprotectores
IT1270993B (it) * 1994-03-18 1997-05-26 Recordati Chem Pharm Derivati chinzolilamminici attivi come alfa-antagonisti
US5623051A (en) * 1994-11-10 1997-04-22 University Of Washington Methods and compositions for screening for presynaptic calcium channel blockers
GB9526560D0 (en) 1995-12-27 1996-02-28 Bayer Ag Use of 2-Amino-Heterocycles
JPH10135749A (ja) * 1996-10-29 1998-05-22 Nec Corp 高周波帯増幅器
EP0870502A3 (en) 1997-04-10 2001-04-04 Kyowa Hakko Kogyo Co., Ltd. Use of adenosine uptake inhibitors for the manufacture of a medicament for the treatment of pancreatitis
IT1293804B1 (it) 1997-08-01 1999-03-10 Recordati Chem Pharm Diarilalchilpiperazine attive sulle basse vie urinarie
AU730364B2 (en) 1997-09-23 2001-03-08 Bristol-Myers Squibb Company Selective cPLA2 inhibitors
PL192083B1 (pl) 1997-11-18 2006-08-31 Dupont Pharmaceuticals Res Lab Pochodne amin cyklicznych i ich zastosowanie
WO1999055688A1 (en) 1998-04-27 1999-11-04 Warner-Lambert Company Substituted diarylalkyl amides as calcium channel antagonists
US6951862B2 (en) * 1998-06-30 2005-10-04 Neuromed Technologies, Inc. Calcium channel blockers comprising two benzhydril moieties
US6011035A (en) 1998-06-30 2000-01-04 Neuromed Technologies Inc. Calcium channel blockers
US6943168B2 (en) * 1998-06-30 2005-09-13 Neuromed Technologies Inc. Calcium channel inhibitors comprising benzhydril spaced from piperazine
US7186726B2 (en) 1998-06-30 2007-03-06 Neuromed Pharmaceuticals Ltd. Preferentially substituted calcium channel blockers
US6310059B1 (en) 1998-06-30 2001-10-30 Neuromed Technologies, Inc. Fused ring calcium channel blockers
US6387897B1 (en) * 1998-06-30 2002-05-14 Neuromed Technologies, Inc. Preferentially substituted calcium channel blockers
US6492375B2 (en) * 1998-06-30 2002-12-10 Neuromed Technologies, Inc. Partially saturated calcium channel blockers
US6268377B1 (en) 1998-09-28 2001-07-31 Merck & Co., Inc. Method for treating androgen-related conditions
US6267945B1 (en) 1998-12-18 2001-07-31 Neuromed Technologies, Inc. Farnesol-related calcium channel blockers
ATE325109T1 (de) * 2000-12-27 2006-06-15 Pola Chem Ind Inc Benzofuranderivate und pharmazeutische zusammensetzungen, die diese enthalten
GB0203299D0 (en) 2002-02-12 2002-03-27 Glaxo Group Ltd Novel compounds
AU2003218737B2 (en) 2002-03-13 2008-04-10 Janssen Pharmaceutica N.V. Inhibitors of histone deacetylase

Similar Documents

Publication Publication Date Title
JP2003503454A5 (enExample)
NO20090095L (no) Anvendelse av en hydrofil matriks omfattende et polyakrylsyrederivat, en cellulose-eter og et disintegreringsmiddel for fremstilling av et medikament for behandling av kvinners genitale forstyrrelser
JP2010535252A5 (enExample)
JP2007523178A5 (enExample)
SI2527315T1 (sl) Spojine, sestavki in metode za zdravljenje amiloidnih bolezni in sinukleinopatij, kot so Alzheimerjeva bolezen, diabetes tipa 2 in Parkinsonova bolezen
IL236426B (en) Use of a compound in combination with bortezomib to prepare a drug for a neoplastic disease and a pharmaceutical preparation containing a compound and bortezomib
IL186303A (en) 1h - benzamideimzole - 4 carboxyamides converted with quarterly carbon in position 2, the pharmaceutical composition containing it and its use for the preparation of a drug @ for the treatment @ of cancer
EP1558220A4 (en) ORAL COMPOSITIONS FOR THE TREATMENT OF DISEASES
HRP20220902T3 (hr) Pripravci i njihova upotreba u liječenju multiple skleroze
EP1979324A4 (en) IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF COGNITIVE DISORDER, MORBUS ALZHEIMER, NEURODEGENERATION AND DEMENTIA.
JP2007514005A5 (enExample)
JP2008534627A5 (enExample)
JP2010518061A5 (enExample)
JP2007536277A5 (enExample)
JP2005507892A5 (enExample)
JP2009538898A5 (enExample)
TWI372056B (en) Novel medicament combinations for the treatment of respiratory diseases
JP2005509503A5 (enExample)
IL179160A0 (en) Substituted n-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies
WO2006113978A3 (en) Insulins combinations
JP2007530703A5 (enExample)
JP2013537901A5 (enExample)
NO20043483L (no) Anvendelse av melagatran for fremstilling av et medikament for behandling av type 1 Diabetes mellitus
JP2008533079A5 (enExample)
JP2008513427A5 (enExample)